PRA Health Sciences (PRA) is dedicated to ensuring quality Aggregate Safety Reports are delivered to our sponsor and MAH partners. Our experienced team of talented Pharmacovigilance professionals offer clear, comprehensive, and effective processes for successful development of Aggregate Safety Reports. Through our use of innovative technologies, the provision of safety data is automated and team review of the Aggregate Safety Reports can be electronically tracked, thereby providing a more streamlined approach to report generation and management.
PRA Leads Novel Multiple Myeloma Drug Development
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract…
Patient Safety and Pharmacovigilance Agreements
Pharmacovigilance Agreements (PVAs) are agreements between two companies based on their Commercial Agreements that require an exchange of safety…
Pharmacovigilance & Patient Safety
Clinical trial participants help us speed breakthroughs in modern drug development. Our job is to protect them.